Business Context and Reporting Period
This Form 8-K Current Report for TherapeuticsMD, Inc. (TXMD) covers events occurring between March 6, 2022, and March 10, 2022. The filing primarily addresses a material divestiture of a subsidiary and a significant amendment to the company's existing financing agreement.
Key Financial Metrics and Agreements
Divestiture of vitaCare
- Transaction: Sale of 100% of vitaCare Prescription Services, Inc. to GoodRx, Inc.
- Consideration: Base cash payment of $150.0 million, subject to customary adjustments and holdbacks.
- Earn-out: Potential additional consideration of up to $7.0 million contingent on vitaCare's financial performance through 2023.
- Expected Closing: Second quarter of 2022, subject to regulatory approvals.
- Post-Closing Arrangements: Long-term services agreement for platform utilization and a 12-month transition services agreement.
Financing Agreement Amendment
- Counterparty: Sixth Street Specialty Lending, Inc. and various lenders.
- Covenant Waivers: Lenders waived breaches of the $60 million minimum cash covenant and minimum net revenue covenants for Q4 2021. The minimum net revenue covenant for Q1 2022 was removed.
- Fee Structure: A $30 million paid-in-kind amendment fee was added to the principal loan amount. $16 million of this fee is waivable under certain conditions.
- Prepayment Penalty: The existing $60 million prepayment penalty was waived.
- Maturity Date: Extended to June 1, 2022.
- Debt Repayment Obligation: The Company must use the first $120 million of net proceeds from the vitaCare divestiture to prepay loans, plus all net proceeds in excess of $135 million.
Material Changes and Financial Condition
The filing references the release of Q4 2021 financial results on March 10, 2022, but does not provide specific revenue, profit, or cash flow figures within the text of this 8-K. The material change in financial condition is driven by the pending divestiture and the restructuring of debt obligations, which includes a significant increase in principal due to the $30 million PIK fee.
Guidance, Outlook, and Risks
- Outlook: Management anticipates the divestiture will close in Q2 2022. Proceeds are earmarked for debt reduction.
- Risks: The transaction is subject to customary closing conditions, including regulatory approvals. Failure to close would impact the company's ability to repay the amended debt obligations as scheduled.
- Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements regarding the divestiture or financial expectations.
Investor Verification Checklist
- Verify the final closing date of the vitaCare divestiture and any adjustments to the $150 million purchase price.
- Confirm the exact amount of the $30 million PIK fee added to the debt principal and the conditions for waiving the $16 million portion.
- Review the Q4 2021 press release (Exhibit 99.1) for specific revenue and earnings figures not detailed in this 8-K.
- Monitor regulatory approval status for the GoodRx transaction to assess the risk of the June 1, 2022, debt maturity.
- Assess the impact of the transition services agreement on future operating expenses.